97306 ⎘
Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Sub-classes:PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#2CLEC9A BINDING AGENTS
#3LAG-3 ANTAGONIST THERAPY FOR MELANOMA
#4NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#5COMPOSITIONS AND METHODS OF DELIVERING LARGE PROTEINS
#6MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA
#7Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors
#8Methods and Treatment Involving Excess Free LIGHT
#9METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
#10THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
#11CD8 BINDING AGENTS
#12BIOPHARMACEUTICAL COMPOSITIONS
#13THE EFFECTIVE AND EFFICIENT CONTROL OF SERUM PHOSPHATE FOR OPTIMAL BONE FORMATION
#14Fc VARIANTS WITH ALTERED BINDING TO FcRn
#15FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
#16ANTI-PD-L1 ANTIBODIES AND METHODS OF USE THEREOF
#17ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#18REDUCING VISCOSITY OF PHARMACEUTICAL FORMULATIONS
#19TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#20ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#21BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD19 AND CD3, AND USES THEREOF
#22BISPECIFIC BINDING MOLECULES
#23TREATMENT FOR ACUTE MYELOID LEUKEMIA WITH ANTI-CD70 ANTIBODIES
#24Fc VARIANTS WITH ALTERED BINDING TO FcRn
#25ANTIBODY VARIANTS AND USES THEREOF
#26METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
#27RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOF
#28METHODS FOR THE TREATMENT OF MULTIPLE MYELOMA
#29HUMAN IGG1 FC REGION VARIANTS AND USES THEREOF
#30ANTI-APOE ANTIBODIES
#31IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
#32ANTIBODY OPTIMIZATION
#33ANTI-ILT2 ANTIBODIES AND USES THEREOF
#34FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFE
#35ANTIBODY VARIANTS AND USES THEREOF
#36SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY
#37Manufacturing Methods for Producing Anti-TNF Antibody Compositions
#38Fc VARIANTS WITH ALTERED BINDING TO FcRn
#39BENZODIAZEPINE DERIVATIVES AND ANTIBODY CONJUGATES THEREOF
#40ANTIBODY MOLECULES TO DENGUE VIRUS AND USES THEREOF
#41CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS
#42BIOPHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
#43Anti-Sclerostin Antibodies and Their Use to Treat Bone Disorders as Part of a Regimen
#44ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF
#45FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE
#46METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS
#47OPTIMIZED ANTI-TL1A ANTIBODIES
#48FORMULATIONS OF ANTIBODY MOLECULES TO DENGUE VIRUS
#49LOW-VISCOSITY ANTIGEN BINDING PROTEINS AND METHODS OF MAKING THEM
#50CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
#51ANTIBODIES SPECIFICALLY BINDING TO MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS
#52METHODS AND COMPOSITIONS FOR TREATING CANCER
#53Fc VARIANTS WITH ALTERED BINDING TO FcRn
#54METHOD FOR ALLOWING IMMUNE CELLS INFILTRATION IN TUMORS
#55ANTI-APOE ANTIBODIES
#56Biopharmaceutical compositions
#57Biopharmaceutical compositions
#58Biopharmaceutical compositions
#59CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME
#60COMPOSITIONS AND METHODS FOR TREATING ALPHA-SYNUCLEINOPATHIES
#61ANTIBODY-UREASE CONJUGATES FOR THERAPEUTIC PURPOSES
#62SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#63COAGULATION FACTOR XI (FXI) BINDING PROTEIN
#64Fc VARIANTS WITH ALTERED BINDING TO FcRn
#65ANTI-TREM-1 ANTIBODIES AND USES THEREOF
#66METHOD FOR ALLOWING IMMUNE CELLS INFILTRATION IN TUMORS
#67Site-Specific Modification of Glycoproteins Through Transglutaminase-Mediated Conjugation
#68COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
#69COMPOSITIONS AND METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS
#70EFFECTIVE AND EFFICIENT CONTROL OF SERUM PHOSPHATE FOR OPTIMAL BONE FORMATION
#71METHODS OF DETERMINING PROTEIN REDUCTION SUSCEPTABILITY
#72Lyophilized powder configured for reconstitution as a liquid pharmaceutical formulation with reduced viscosity and method of preparing thereof
#73ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#74METHODS AND TREATMENT INVOLVING EXCESS FREE LIGHT
#75ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
#76RSV-specific antibodies and functional parts thereof
#77ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
#78Chimeric polypeptide assembly and methods of making and using the same
#79Anti-coagulation factor XI antibodies
#80ANTIBODY MOLECULES WHICH BIND CD45
#81Heavy Chain Constant Regions with Reduced Binding to Fc Gamma Receptors
#82ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#83PRODUCTION OF HETERODIMERIC PROTEINS
#84LOW-VISCOSITY, HIGH CONCENTRATION EVOLOCUMAB FORMULATIONS AND METHODS OF MAKING THE SAME
#85HUMANIZED ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF
#86BINDING MOLECULES WITH MODIFIED J-CHAIN
#87Tissue factor-targeted antibody-drug conjugate
#88Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer
#89FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
#90PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#91Site-specific antibody-drug conjugates by ADP-ribosyl cyclases
#92Subcutaneous HER2 antibody formulations
#93INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#94ANTIGEN-BINDING AND ANTIGEN DEGRADATION CONSTRUCTS
#95Anti-ApoE antibodies
#96TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#97BIOPHARMACEUTICAL COMPOSITIONS
#98COMBINATION THERAPY OF CARBOPLATIN AND NAPI2B-TARGETED POLYMER ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF OVARIAN CANCER
#99CD123 binding proteins and related compositions and methods
#100CLEC9A BINDING AGENTS
#101ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#102BISPECIFIC BINDING MOLECULES
#103ANTI-TL1A/ANTI-TNF-ALPHA BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#104ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME
#105Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#106METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
#107Biopharmaceutical compositions
#108CD8 BINDING AGENTS
#109Antibody molecules to dengue virus and uses thereof
#110Methods of Engineering Surface Charge for Bispecific Antibody Production
#111ROR1 ANTIBODY COMPOSITIONS AND RELATED METHODS
#112Manufacturing methods for producing anti-TNF antibody compositions
#113J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE
#114Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
#115Methods for treating tumor-induced osteomalacia
#116Conditionally active biological proteins
#117KRAS SPECIFIC ANTIBODIES AND USES THEREOF
#118RSV-specific antibodies and functional parts thereof
#119METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY
#120PHOTOACTIVE ANTIBODIES
#121Anti-CD20 antibody
#122Activatable interleukin-2 polypeptides and methods of use thereof
#123Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#124Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#125Nucleic acids encoding anti-TREM-1 antibodies
#126Anti-TREM-1 antibodies and uses thereof
#127Activatable interleukin-2 polypeptides and methods of use thereof
#128Low-viscosity antigen binding proteins and methods of making them
#129ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
#130ANTI-RSPO3 ANTIBODIES AND METHODS OF USE
#131ROR2 antibody compositions and related methods
#132Biopharmaceutical compositions
#133Biopharmaceutical compositions
#134Biopharmaceutical compositions
#135Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
#136Fc variants with altered binding to FcRn
#137Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
#138BISPECIFIC BINDING MOLECULES
#139Conjugates of a glycoprotein or a glycan with a toxic payload
#140Human Anti-Tau Antibodies
#141MONOCLONAL ANTIBODY INHIBITOR OF FACTOR XIIA
#142Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody
#143Proteins specific for BAFF and B7RP1 and uses thereof
#144Antibodies against BACE1 and use thereof for neural disease immunotherapy
#145ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS
#146Antibody variants and uses thereof
#147ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS
#148Optimized variants of anti-VEGF antibodies
#149Fusion Protein Constructs Comprising an Anti-MUC1 Antibody and IL-15
#150ACTIVATABLE ANTI-CD166 ANTIBODIES AND METHODS OF USE THEREOF
#151CONJUGATES OF CYSTEINE ENGINEERED ANTIBODIES
#152SUBCUTANEOUS HER2 ANTIBODY FORMULATIONS
#153Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
#154Compositions and methods for antibodies targeting BMP6
#155Fusion proteins for ophthalmology with increased eye retention
#156Activatable antibodies that bind epidermal growth factor receptor and methods thereof
#157Factor IX polypeptides and methods of use thereof
#158Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins
#159Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#160FACTOR IX POLYPEPTIDES AND METHODS OF USE THEREOF
#161Polynucleotides encoding anti-C1s antibodies
#162FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME
#163Anti-annexin A2 monoclonal antibodies
#164Methods for determining DPP3 and therapeutic methods
#165Inert format
#166RSV-specific antibodies and functional parts thereof
#167Methods for treating hypophosphatemic disorders
#168Anti-coagulation factor XI antibodies
#169Anti-TREM2 antibodies and methods of use thereof
#170Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
#171Anti-coagulation factor XI antibodies
#172Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers
#173ROR1 antibody compositions and related methods
#174METHODS OF TREATING DISEASES
#175Antibodies to TIGIT
#176ANTI-SERUM ALBUMIN BINDING VARIANTS
#177Activatable interleukin-2 polypeptides and methods of use thereof
#178Humanized antibodies against CEACAM1
#179Methods of treating ankylosing spondylitis using IL-17 antagonists
#180Anti-coagulation factor XI antibodies
#181Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
#182Binding molecules with modified J-chain
#183Anti-coagulation factor XI antibodies
#184Optimized anti-TL1A antibodies
#185Formulations of antibody molecules to dengue virus
#186Heterodimeric antibodies that bind CD3 and PSMA
#187Polynucleotides encoding humanized antibodies against CEACAM1
#188Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof
#189Conditionally active biological proteins
#190Humanized or chimeric CD3 antibodies
#191BIOPHARMACEUTICAL COMPOSITIONS
#192Methods of neutralizing IL-8 biological activity
#193CD123 binding proteins and related compositions and methods
#194Optimized anti-TL1A antibodies
#195Anti-CLL-1 antibodies and methods of use
#196Method for measuring viscosity of protein solution
#197Anti-transferrin receptor antibodies and methods of use
#198HUMANIZED OR CHIMERIC CD3 ANTIBODIES
#199Antibody-cytokine engrafted proteins and methods of use for immune related disorders
#200Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#201Heavy chain constant regions with reduced binding to Fc gamma receptors
#202Engineered immunoglobulin Fc polypeptides displaying improved complement activation
#203Modified variable domain molecules and methods for producing them
#204Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#205CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS
#206Anti-Zika virus antibodies and methods of use
#207ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#208Production of heterodimeric proteins
#209METHODS FOR ADMINISTERING ANTI-IL-5 ANTIBODIES
#210Activatable interleukin-2 polypeptides
#211ß-1,6-glucan therapeutic antibody conjugates
#212METHODS FOR TREATING CHRON'S DISEASE USING AN ANTI-IL23 ANTIBODY
#213Bispecific signaling agents and uses thereof
#214Biomarkers for anti-IL4-IL13 bispecific antibodies
#215Clec9A binding agents
#216Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
#217Antibody-drug conjugate having cyclic benzylidene acetal linker
#218J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
#219Erenumab compositions and uses thereof
#220Anti-TREM-1 antibodies and uses thereof
#221Non-adult human dosing of brentuximab vedotin
#222Anti-ApoE antibodies
#223CD20 antibodies
#224FABS-IN-TANDEM IMMUNOGLOBULIN AND USES THEREOF
#225Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
#226NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#227Low-viscosity antigen binding proteins and methods of making them
#228Human Anti-Tau Antibodies
#229Fusion proteins for opthalmology with increased eye retention
#230PAC1 antibodies and uses thereof
#231Antibodies Against Tissue Factor Pathway Inhibitor
#232Anti-CSF1R antibody and anti PD-1 antibody combination therapy for cancer
#233Tissue factor-targeted antibody-drug conjugate
#234Factor IX polypeptides and methods of use thereof
#235Factor IX polypeptides and methods of use thereof
#236Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity
#237Anti-CD20 antibody
#238Anti-annexin A2 monoclonal antibodies
#239Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
#240Antibody binding to carbonic anhydrase and use thereof
#241Chimeric polypeptide assembly and methods of making and using the same
#242Antibody molecules to dengue virus and uses thereof
#243METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS
#244Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
#245Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
#246ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#247TREATMENT FOR ACUTE MYELOID LEUKEMIA
#248RSV-specific antibodies and functional parts thereof
#249Optimized variants of anti-vegf antibodies and methods of use thereof in treatment
#250Antibodies specific for enteroviruses that infect humans
#251Therapy involving antibodies against Claudin 18.2 for treatment of cancer
#252CD8 binding agents
#253POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS & ANTAGONISTS
#254Anti-TREM2 antibodies and methods of use thereof
#255Method for producing antibody
#256Antibody molecules to CD73 and uses thereof
#257Methods of engineering surface charge for bispecific antibody production
#258ROR2 antibody compositions and related methods
#259Polynucleotides encoding optimized variants of anti-VEGF antibodies
#260Methods for improving safety of blood-brain barrier transport
#261Conditionally active biological proteins
#262Monoclonal antibody inhibitor of factor XIIA
#263Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#264ROR1 antibody compositions and related methods
#265Biopharmaceutical compositions and related methods
#266Anti-OX40 antibody and application thereof
#267Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
#268Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#269METHODS FOR TREATING CROHN'S DISEASE USING AN ANTI-IL23 ANTIBODY
#270ANTI-IL-17A AND IL-17F CROSS REACTIVE ANTIBODY VARIANTS AND COMPOSITIONS COMPRISING AND METHODS OF MAKING AND USING SAME
#271Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
#272Subcutaneous HER2 antibody formulations
#273PRODUCTION OF HETEROMULTIMERIC PROTEINS
#274CD3 binding polypeptides
#275Binding molecules with modified J-chain
#276Nucleic acids encoding IL-8 antibodies
#277Glycoprotein-toxic payload conjugates
#278Antibody Fragments Against the Insulin Receptor and Uses Thereof to Treat Hypoglycemia
#279Fusion immunomodulatory proteins and methods for making same
#280Biopharmaceutical compositions comprising interleukin-5 antibody
#281LIQUID ANTIBODY FORMULATION WITH IMPROVED AGGREGATION PROPERTIES
#282Antibody molecules which bind CD45
#283Monoclonal antibody neutralizing infectivity of all ebola viruses
#284Low-viscosity, high concentration evolocumab formulations and methods of making the same
#285Library-based methods and compositions for introducing molecular switch functionality into protein affinity reagents
#286Factor IX Polypeptides and Methods of Use Thereof
#287Factor IX polypeptides and methods of use thereof
#288Extension sequences for diabodies
#289Factor IX Polypeptides and Methods of Use Thereof
#290IL2Rbeta/common gamma chain antibodies
#291Anti-TIGIT antibodies and methods of use
#292Tri-specific antibodies for HIV therapy
#293Compositions and methods for antibodies targeting BMP6
#294Fc VARIANTS WITH ALTERED BINDING TO FcRn
#295COVALENT DISULFIDE-LINKED DIABODIES AND USES THEREOF
#296Phage display library, members thereof and uses of the same
#297Antibodies specifically binding to MASP-3 for the treatment of various diseases and disorders
#298Anti-transferrin receptor antibodies and methods of use
#299Bispecific multivalent fusion proteins
#300Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen